


# Cervical Cancer Module Update EORTC QLQ-CX


Quality of Life Group Meeting  
March 2005  
Brussels



# Cervical Cancer

---


- Second most common cause of cancer mortality amongst women worldwide
- The incidence is dropping in developed countries due to effective screening programs
- The five year survival rate for early stage disease (stage I) is 90 % for advanced stage below 10 %



# Cervical Cancer: Treatment

---


- Curative treatment for earlier stages: pelvic surgery and radiotherapy
  - For locally advanced or for recurrent disease radiotherapy is the standard treatment
  - Concomitant chemo/radiotherapy following surgery has demonstrated promising results in terms of survival
  - Different treatment modalities have an impact on QoL
-



## Development of a Module for Assessing QoL of Cervical Cancer Patients

---


- Symptoms related to cervical cancer
  - Treatment related issues for patients undergoing pelvic surgery and/or concomittant chemo/radiotherapy
  - Additional QoL issues (sexuality, body image, menopausal symptoms)
  - Supplemented to the core questionnaire
-



# Development of the CX Module

---

- Phase I:** Generation of QOL issues
- Phase II:** Construction of items  
Phase I/II report submitted to MDC  
and accepted 2003
- Phase III:** Pre/pilot - testing  
Patient interviews in 11 countries  
Phase III report submitted to MDC
- Phase IV:** Field - testing (in preparation)
-



## EORTC QLQ-CX Module

---

### Multi-item subscales

**GI:** Gastrointestinal symptoms

**URO:** Urological symptoms

**VA:** Vaginal symptoms

**BI:** Body image

**SF:** Sexual functioning

### Single item scales


**MS:** Menopausal symptom

**LY:** Lymphoedema

**BP:** Back pain

**PN:** Peripheral neuropathy

---




## Phase III: Pre/pilot-testing the module

---

To identify and solve problems with the translated items

- difficult to answer
  - confusing
  - difficult wording
  - upsetting/offensive
  - suggestions for different wording
-




Country	Collaborator	Patients
---------	--------------	----------

Australia	Duric/Hacker	7
Austria	Greimel/Bjelic/Mautner	15
Brazil	deSouza	5
Croatia	Kuljanic - Masic	15
Denmark	Jensen	14
Germany	Singer/Fehlauer	21
Korea	Yun HY	21
NL	Incrocci/Creutzberg	27
Poland	Wydra	31
Sweden	Waldenström/Bergmark	17
Taiwan	Chie	27
UK	Nordin/Swift/Routledge	16


12 countries

N=216




## Patient characteristics N=216

		N	%
<b>Age:</b>	Mean 52 yrs (SD 14)		
<b>Education:</b>	Compulsory or less	97	45
	Post - compulsory	95	44
	University level	24	11
<b>Employment:</b>	Full/part time	76	35
	Homemaker	48	22
	Retired	46	21
	Unemployed/other	46	21
<b>Living:</b>	Alone	33	15
	With partner/family	177	82
	With others	6	3



## Cancer Stage: Cross-cultural distribution

<b>Country</b>	<b>FIGO I</b>	<b>II</b>	<b>III</b>	<b>VI</b>
Australia	4		1	
Austria	9	6		
Brazil		1	4	
Croatia	9	3	3	
Denmark	5	6	3	
Germany	3	5	8	4
Korea	11	7	1	2
NL	3	7	16	
Polen	23	7	1	
Sweden	9	4	2	
Taiwan	19	6	1	1
UK	7	7	1	
	102	59	41	7




## Treatment

---

Pelvic Surgery	134
Chemotherapy	72
Radio/chemotherapy	18
Brachytherapy	78
External Beam	102

---

Under active treatment	105
Treatment completed	111



## Qualitative results


---

72 % made no comments  
28 % made comments

Difficult to answer	9 %
Confusing items	12 %
Difficult wording	14 %
Upsetting	5 %

Sexuality items: 36 % completed the items  
64 % not relevant (missing data)

---



## Quantitative results

---

16 items remained unchanged


8 items were slightly modified (reworded)

2 items were deleted

6 items did not meet the criteria (mean  $< 1.5$ )

1 item had a range  $< 3$

---



# EORTC QLQ CX-24

---

## Phase IV: International Field Study

- to test the psychometric properties
- to determine the cross-cultural applicability
- to confirm the hypothesized scale structure

**Joint protocol with EORTC GCG?**

---